Skip to content

Author

A. Fagiolini

7 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov.

BACKGROUND Incretin-based therapies, including conventional glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1-containing co-agonists, are being repurposed for psychiatric disorders. The breadth and maturity of the randomized pipeline are easily misread. METHODS We searched ClinicalTrials.gov on 1 Septemb...

A. Fagiolini, A. Cuomo · 0 citations
Open access Oct 2026

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

Neuroplasticity, the brain’s capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [¹¹C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprote...

C. Agnorelli, J. Peill, D. Kurtin et al. · 0 citations
Open access Sep 2026

620. Facilitating gender equity in neuropsychopharmacological clinical research

Abstract Background Depressive and anxiety disorders are significantly more common in women than in men [1]. Despite higher prevalence, there is paucity of published evidence on the evaluation of efficacy and safety of drugs used for these conditions in women [2]. Various guidelines recommend inclusion of women and min...

C. Correll, A. Fagiolini, M. P. Mariano et al. · 0 citations
Review Aug 2026

Profiling intranasal esketamine for adults with major depressive disorder and acute suicidal ideation or behavior: a phenotype-informed drug profile

ABSTRACT Introduction Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketam...

M. Pinzi, A. Cuomo, M. B. Rescalli et al. · 0 citations
Open access Sep 2026

530. Detecting neuroplastic effects induced by ketamine and classic psychedelics in healthy human subjects

Abstract Background Clinical studies have shown that ketamine and classic psychedelics can produce robust and rapid antidepressant effects after a single or a few administrations. However, the neurobiological mechanisms driving these long-lasting changes remain unclear. A leading framework proposes that both drug class...

C. Agnorelli, J. Peill, D. Kurtin et al. · 0 citations
Review Open access Sep 2026

Childhood ADHD and Its Adult Mimics: When First-Time ADHD Diagnoses in Adulthood May Reflect Other Conditions—A Narrative Review

Highlights What are the main findings? ADHD changes across development, shifting from overt hyperactivity and impulsivity in childhood toward inner restlessness, executive dysfunction, disorganization, and impaired self-regulation in adulthood. The recent increase in adult ADHD diagnoses is compatible with several over...

A. Cuomo, M. Pinzi, A. Fagiolini · 0 citations
Open access Sep 2026

576. Alprazolam for symptom relief: addressing the more troublesome features of anxiety disorders

This post-hoc analysis of clinical studies of alprazolam demonstrated the effect of its short-term use in alleviating autonomic hyperactivity, tension, and intellectual issues and may offer a neurobiological basis for GAD.

S. Shirol, S. Awasthi, A. Fagiolini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.